【Heavy】World Stroke Day| The first expert recommendation for the treatment of stroke by Tongxinluo was officially released

On October 29, 2022, coinciding with the 17th World Stroke Day, at the opening ceremony of the 3rd Annual Academic Conference of the Shanghai Stroke Society and the 16th China Neurology Forum (CNF2022), China's first expert recommendation on the clinical application of Tongxinluo Capsules in the field of atherosclerotic cerebrovascular disease (hereinafter referred to as the "Expert Recommendation") was officially released
.

Professor Dong Qiang, deputy director of the National Medical Center for Neurological Diseases (Huashan) and affiliated to Huashan Hospital of Fudan University, pointed out at the press conference that stroke is the number one cause of
death and disability among Chinese residents.
Effective stroke prevention and control is of great
significance to achieving the strategic goal of a healthy China and reducing poverty in China.

As a representative proprietary Chinese medicine for the treatment of cardiovascular and cerebrovascular diseases in China, Tongxinluo capsules have been widely used and recognized
in clinical practice for more than 20 years.
Professor Dong Qiang introduced that the "Expert Advice" written this time provides an application "portrait"
for people who may benefit from the use of Tongxinluo capsules in the cerebrovascular field.
Clinicians can follow this "portrait" in practice and use
it in a standardized manner among the corresponding patient population.
Help patients delay the progression of atherosclerosis and reduce the occurrence and recurrence
of stroke.

Group photo of experts at the launch of "Expert Advice"

Expert Advice provides application "profile"

Guide clinical standard diagnosis and treatment

"The expert group held 45 symposiums before and after, experienced multiple rounds of expert demonstration, based on the existing literature evidence, combined with expert discussion opinions and clinical use experience, and finally published the Department's Expert Recommendations
.
" Professor Zhao Yiquan, a member of the expert group, deputy head of the cerebrovascular disease group of the Chinese Medical Association Neurology Branch and Beijing Tiantan Hospital affiliated to Capital Medical University, expressed the hope that the "Expert Advice" can serve the clinic and allow clinicians to apply Tongxinluo capsules
more standardly.

At the meeting, Professor Wang Dandan, author of the Expert Advice and Beijing Tiantan Hospital affiliated to Capital Medical University, shared
the main contents of the Expert Advice.
Professor Wang Dandan introduced that the Tongluo treatment method has created a new way to prevent and treat cardiovascular and cerebrovascular diseases, and the "Expert Recommendations" analyzed and summarized the components of Tongxinluo capsules and their safety in atherosclerosis, stroke, cardiovascular diseases and put forward the following suggestions:

(1) In the treatment of atherosclerosis, it is recommended that the application of Tongxinluo capsules can improve the progression of atherosclerotic plaque and may reduce the occurrence of cardiovascular and cerebrovascular diseases (level II.
a recommendation, level A evidence);

(2) In the treatment of stroke, it is recommended that the use of Tongxinluo capsules in patients with acute ischemic stroke can improve their symptoms of neurological deficit and may reduce the recurrence rate of long-term cerebrovascular events (level II.
b recommendation, level B evidence);

(3) In the treatment of cardiovascular diseases, it is recommended that Tongxinluo capsules can be used in combination with conventional double antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome with platelet hyperresponsiveness, and may be effective for secondary prevention in clinical practice (level II.
a recommendation, level B evidence);

(4) In terms of clinical application safety, it is recommended that the incidence of adverse neurological reactions treated with Tongxinluo capsules is lower than that of chemical drugs alone, and the incidence of adverse events of various types is comparable to that of the control group, and the overall safety is acceptable for clinical treatment (level II.
a recommendation, level B evidence).

Experts at the meeting pointed out that the "Expert Recommendations" released this time focus on the key issues in the clinical application of Tongxinluo capsules, organically combining evidence-based medical literature evidence and the clinical experience of multidisciplinary experts to make it closer to clinical practical application
.

Inherit the model of innovation

Tongxinluo has great potential for clinical application

Based on the series of research evidence of Tongxinluo capsules, the participating experts also put forward suggestions
for the future research direction of Tongxinluo capsules in the field of cerebrovascular.

Cerebral small vessel disease is closely related to microcirculation, and the cognitive dysfunction caused by it also occupies a very large proportion in clinical practice
.
"Tongxinluo capsules have definite evidence
in brain protection, improving microcirculation, such as improving the blood-brain barrier, microvascular endothelial cell function and microvascular spasm, improving the neurotoxic effects of excitatory amino acids, and reducing brain reperfusion injury 。 Professor Luo Benyan, deputy head of the Neuropsychological and Behavioral Neurology Group of the Neurology Branch of the Chinese Medical Association and the First Affiliated Hospital of Zhejiang University School of Medicine, pointed out that based on the series of research evidence of Tongxinluo capsules and their large-sample, multi-center clinical research (TISS study) in the field of cerebrovascular diseases, Tongxinluo capsules may also play a very good role
in cognitive dysfunction in the future.

Professor Wang Lijuan, vice president of the Neurologist Branch of the Chinese Medical Doctor Association and Guangdong Provincial People's Hospital, introduced that cerebral small vessel lesions can cause many dysfunctions, such as cognitive dysfunction, motor dysfunction, parkinsonism and emotional disorders
.
"Small vessel lesions themselves have a certain concealment, is a gradual progression of the disease, easy to overlook
.
" Professor Wang Lijuan pointed out that in terms of the mechanism of action, Tongxinluo capsules focus more on protecting microvessels, improving microcirculation and inhibiting plaque progression
.
In the future, Tongxinluo capsules should pay more attention to the secondary prevention of ischemic stroke or cerebral small vessel disease related to cerebral small vessel disease, so that more patients can benefit
.

In an interview with the media at the meeting, Professor Dong Qiang pointed out that in January 2020, the project "Construction of Traditional Chinese Medicine Context Theory and Its Guidance for the Prevention and Treatment of Microvascular Lesions" with Tongxinluo capsule series research as the main content won the first prize of the annual National Science and Technology Progress Award, which is very valuable and a model of
traditional Chinese medicine inheritance and innovation.
It is hoped that more Chinese medicine will participate in the future and confirm the contribution
of the motherland's medicine to modern medicine.

It is reported that Tongxinluo capsules plan to carry out a number of large-sample, multi-center, randomized controlled, high-quality clinical studies, especially for stroke patients of different etiologies, such as secondary prevention of cerebrovascular disease patients with intracranial artery stenosis or small vessel lesions
.
It is expected that it can obtain more clinical evidence, further guide clinical medication, and benefit the majority of patients
.

Typesetting: Hu Haiyan

Editor: Hu Haiyan

Reviewed: Qin Miao

The power to move the industry forward! The report of the 7th Medical Scientist Summit 2022 is here!

The 2022 "Physician Daily" is under order!!! Millions of doctors are watching.
.
.

"Physician Daily" public mailbox: yishibao2017@163.
com

[Note] Some pictures come from the Internet and WeChat Moments, if there is infringement, please contact to delete, thank you! Tel: 010-58302828-6808

At present, 1130000+ doctors have paid attention to join us